Drug intelligence / Profile preview

HTPEP-002

Development stage: Preclinical
Lead developer: Chengdu Huitai Biomedical
Modality: Peptides

Overview

HTPEP-002 is a peptide-based therapeutic candidate developed by Chengdu Huitai Biopharmaceutical for the treatment of liver cirrhosis and liver fibrosis. As part of the company's expanded TGF-β targeted pipeline, HTPEP-002 is designed to inhibit Transforming Growth Factor beta 1 (TGF-β1) signaling, which is a central mediator in the progression of tissue fibrosis. By targeting TGF-β1, the drug aims to suppress the activation of myofibroblasts and the subsequent excessive deposition of extracellular matrix in the liver. HTPEP-002 is currently in the preclinical stage of development.

Targets

THBS1 (Thrombospondin-1)

Beyond the preview

Go deeper on HTPEP-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HTPEP-002.

Explore the full profile